Tag: nintedanib Ofev

All

New Guidance for Treating Systemic Sclerosis-associated ILD

A new ATS clinical practice guideline recommends expanding antifibrotic treatment to all patients with systemic sclerosis associated with ILD, not just those with progressive disease.

FDA Accepts sNDA for ILD Drug in Children and Adolescents
FDA Approves Ofev for Progressive Interstitial Lung Diseases
Ofev Tagged a Breakthrough Therapy After Positive Ph3 Results
Ofev Approved by FDA for SSc-ILD
Ofev Slows Pulmonary Function Loss in SSc-ILD
Ofev Preserves Pulmonary Function of IPF Patients Awaiting a Lung Transplant
Trial to Evaluate Ofev Impact on Predictive Biomarkers for IPF Progression Begins

All

New Boehringer Data Reinforces Ofev Efficacy, Safety for IPF

New analyses presented at ATS 2016 further add to the efficacy and safety profile of Ofev (nintedanib) in idiopathic pulmonary fibrosis (IPF).

Consistent Efficacy of OFEV with Idiopathic Pulmonary Fibrosis
FDA Accepts NDA Filing for Boehringer’s IPF Drug Nintedanib
Two Promising Drug Therapies For Pulmonary Fibrosis

Tag: nintedanib Ofev

All

New Guidance for Treating Systemic Sclerosis-associated ILD

FDA Accepts sNDA for ILD Drug in Children and Adolescents

FDA Approves Ofev for Progressive Interstitial Lung Diseases

Ofev Tagged a Breakthrough Therapy After Positive Ph3 Results

Ofev Approved by FDA for SSc-ILD

Ofev Slows Pulmonary Function Loss in SSc-ILD

Ofev Preserves Pulmonary Function of IPF Patients Awaiting a Lung Transplant

Trial to Evaluate Ofev Impact on Predictive Biomarkers for IPF Progression Begins

All

New Boehringer Data Reinforces Ofev Efficacy, Safety for IPF

Consistent Efficacy of OFEV with Idiopathic Pulmonary Fibrosis

FDA Accepts NDA Filing for Boehringer’s IPF Drug Nintedanib

Two Promising Drug Therapies For Pulmonary Fibrosis

All

Sorry, No Posts Found

Sorry, No Posts Found

Respiratory Therapy

Our Parent Company

Key Resources

Helpful Links